Cannabinoids Lead to Marijuana Biotech

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
336
Cannabinoids Lead to Marijuana Biotech Boom

NetworkNewsWire Editorial Coverage: As the legalization of medical marijuana spreads, the appetite for investment in the cannabis biotech sector keeps growing. This is the largest sector of the legal cannabis market, already a multi-billion-dollar market. Researchers continue to uncover new ways that cannabinoids, chemical compounds found in cannabis, can be used as medicine. Earth Science Tech (ETST) (ETST Profile) offers full-spectrum, high-grade hemp cannabidiol (CBD) oil, and is researching cutting-edge CBD products through its subsidiary Cannabis Therapeutics, Inc. (CTI). The creator of the first cannabis-based prescription medicine, GW Pharma (GWPH) is working on new drugs to tackle epilepsy, while Medical Marijuana, Inc. (MJNA) provides a range of CBD oils with medical and nutritional benefits to customers across North and South America. CV Science, Inc. (CVSI) utilizes separate drug development and consumer product divisions to create and market a diverse range of CBD products to a variety of markets, and Cannabis Science, Inc. (CBIS) is developing formulation-based drugs based on cannabinoid science.

A Thriving New Sector

The legal cannabis sector is booming. According to the Brightfield Group, it is already worth over $7 billion and expected to grow to $31 billion by 2021. Within that market, CBD products are a significant sector, expected to hit $1 billion in the next few years. Even the more conservative U.S. states are overcoming their objections and opening up to CBD production and sales, as legislators seek to resolve legal ambiguities in favor of patients.

While the emergence of a recreational cannabis market in regions such as Canada and California is exciting news for the cannabis industry, the industry’s financial security rests on medical products. The loosening of laws makes research easier, as does the growing experience of medical cannabis companies. CBD is a particularly rich source of therapeutics with the potential to be utilized against a wide range of ailments. Researchers are exploring its potential to tackle such enduring problems as epilepsy, anxiety, depression and breast cancer.

Innovating in Cannabidiol

Biotechnology company Earth Science Tech (ETST) has diverse interests within the cannabis market. Its subsidiaries cover diagnostics and vaccines, recreational cannabis and CBD products. In that last area, it’s leading the way in researching and marketing a wide variety of CBD-based treatments through innovative partnerships and collaborative research.

Earth Science Tech’s CBD work is carried out through its subsidiary Cannabis Therapeutics, Inc. (CTI). The company’s CBD oil is 100 percent natural and organic, catering to the environmental concerns common among cannabis users. It is made using a CO2 liquid extraction process that results in a full-spectrum, high-grade hemp CBD oil that has the highest purity and quality on the market.

To keep it in the lead of the CBD market, Earth Science Tech has created partnerships with other research bodies to produce cutting-edge treatments. It is working with the University of Central Oklahoma and DV Biologics Laboratory on research and development projects to enhance the healthcare benefits of its CBD oil. This has positioned the company to take a leadership role in the development of cannabinoid-based pharmaceutical and nutraceutical products. The company holds a provisional application patent for a CBD product for treating breast and ovarian cancers, taking CBD treatments in bold new directions.

Reaching New Market Sectors

Cannabis Therapeutics currently has two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products in development. These are being made to treat a range of ailments including anxiety, depression and fatty liver disease.

One major focus is integrating the CBD molecule with existing generic drug molecules to create more efficient medications that have fewer side effects than the more common approaches. The company is therefore engaged not only in making cannabinoids useful and available to a wider range of patients, but in creating a better experience for existing patients.

Other research into medical cannabinoids by Earth Science Tech could counter conservative fears about the impact of medical cannabis on the illegal drug market. In November 2017, the company began human trials on a new CBD formula designed to decrease cravings and the negative effects of withdrawal in opioid addicts. Based on industrial hemp CBD mixed with a natural ingredient that increases dopamine levels, it could be used to counter the opioid epidemic plaguing many countries. By turning medical CBD into a weapon in the fight against addiction, it will reposition cannabis in the public discourse on drug use. This has the potential to counter resistance to the expansion of the medical cannabis market.

Raising the Brand Profile

Earth Science Tech has a wide variety of products, giving it good reach within the CBD market. Its CBD treatments are available as vitamins, minerals, herbs, botanicals, personal care products, homeopathic treatments and foods. Other products come in forms including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Available at retail stores across the United States and online, they have a combination of physical shelf presence and online visibility to raise their profile with consumers.

The company is currently rebranding its CBD products (http://nnw.fm/s6pC1), using market research to drive improved sales. The chief marketing officer commented, “We did a lot of market research to see what the best angle to truly stand out in the growing CBD industry is through our accounts, representative feedback, and external brand analysis. I feel that marketing, ‘High Grade Full Spectrum Cannabinoids’ will help ETST truly stand out. Soon, the market will be able to see that ETST is a true full spectrum CBD brand, especially with the cannabinoid complex listing under the supplement facts.”

As a result of this research, previous marketing of the company’s products as, “High Grade Hemp CBD Oil” is being replaced with “High Grade Full Spectrum Cannabinoids.” Branding will also include the addition of “Cannabinoid Complex”. The supplement facts will show the breakdown of the full spectrum of CBD oils being used, including CBD, CBG and CBDA.

Box packaging has been designed to incorporate these changes and a modern, edgy look while maintaining the clean design associated with medicinal products.

Better Distribution

Taking these revamped products into American stores (http://nnw.fm/pd51A) is the first major distributor for Earth Science Tech’s products — Mr. Checkout.

Mr. Checkout, as featured on ABC’s Shark Tank, is a national group of independent distributors, full-line grocery distributors and convenience stores. It represents products in over 60 major U.S. retail outlets with approximately 55,000 stores. Mr. Checkout’s accounts include Walgreens, CVS, Walmart, Wholefoods Market and Target. This distribution deal provides a direct route for Earth Science Tech’s products onto the shelves of powerful retail stores with a large consumer base.

Earth Science Tech has 10 active representatives opening and managing accounts across the United States. These representatives have been very successful with health food stores and clinics. The distribution agreement with Mr. Checkout will take the company’s products beyond this market, into major retailers and stores, substantially expanding the company’s reach.

Gabriel Aviles, Earth Science Tech’s chief sales officer and director, said about the deal, “I feel that we have finally put together a solid productive team of representatives that we needed to continue expanding our presence in health shops and clinics. Now, with Mr. Checkout, we will be able to take our presence and sales to the next level, entering larger retailers and many stores. 2018 looks to be starting off very strong with our new product revamp, marketing and education strategy, and sales channel.”

Growing Consumer Choice

The growth of the medical cannabis sector means that Earth Science Tech’s products sit among a wide range of brands on the ever-growing shelves of CBD oils.

British cannabis company GW Pharma (GWPH) has developed Sativex, the first prescription medicine derived from the marijuana plant. This has been approved for Multiple Sclerosis spasticity and neuropathic pain in 29 countries. The company is currently seeking FDA approval for Epidiolex, a CBD-based treatment for epilepsy, after the drug was found to be effective in clinical trials.

Medical Marijuana (MJNA), one of the pioneers of the cannabis sector in North and South America, offers its flagship product Real Scientific Hemp Oil (RSHO) in three varieties. RSHO was the first legal CBD oil in both Brazil and Mexico, and the company was the first publicly traded cannabis business in the United States. A global leader in the medical marijuana industry, this forward-looking company is also exploring the nutritional potential of hemp.

CV Science (CVSI) is divided into two segments: a drug development division focused on creating and commercializing novel CBD-based therapeutics, and a consumer product division that manufactures, markets and sells plant-based CBD products. It is tapping into a wide range of market sectors through products such as its Purified Liquids products for vaping. Its PlusCBD Oil is the top-selling brand of hemp-derived CBD oil for consumers in the natural products industry.

Recognizing the long history of cannabinoids for health purposes and supporting peer-reviewed scientific journals, Cannabis Science (CBIS) is focused on the discovery and development of novel cannabinoid-based therapies as treatment options for unmet medical needs. Its immediate focus is on the treatment of cancer.

Cannabinoids are an increasingly important part of the growing cannabis sector. Companies that can combine strong branding, customer outreach and innovative products are likely to see great growth as the market expands by billions each year. And as research finds new therapeutic uses for these chemicals, they are set to improve the lives of thousands of patients.

For more information on Earth Science Tech, visit Earth Science Tech (ETST)

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Earth Science Tech, Inc. (ETST) Stock Research Links

ETST Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 501

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 595

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Initiated for Voyager Therapeutics Investors

Updated Category News Views 115

Investigation Overview for Voyager Therapeutics Investors Pomerantz LLP is currently exploring possible claims on behalf of investors in Voyager Therapeutics, Inc. (NASDAQ: VYGR). This exploration arises from concerns surrounding the company’s recent announcements and operational strategies. Details of the Investigation The inquiry focuses on whether Voyager and some of...

Continue Reading
Subway's Creative Middle Seat Reward for Travelers

Updated Category News Views 132

Subway Announces Exciting Promotion for Air Travelers On January 27, a significant change is happening for travelers, especially for those who dread sitting in the middle seat of a plane. With a popular airline ending its open seating policy, millions are gearing up for assigned seating. This means that many passengers might find themselves in the middle seat, which is...

Continue Reading
Expanse Studios Unveils Innovative Games at Major Summit

Updated Category News Views 86

Expanse Studios Shines at Industry Summit Expanse Studios, a cutting-edge gaming developer and a subsidiary of Golden Matrix Group Inc. (NASDAQ: GMGI), has made a significant impression at the recent SBC Summit Lisbon. This event attracted around 25,000 attendees, featuring a mix of gaming innovators and industry experts, all eager to explore what's next in the gaming...

Continue Reading
Unlocking Digital Preservation Skills Through New Academy

Updated Category News Views 150

Introducing the Preservica Academy for Digital Preservation Preservica Inc. has unveiled its exciting new initiative, Preservica Academy, dedicated to enhancing the skills of professionals and beginners in the realm of digital preservation. This innovative program focuses on Active Digital Preservation™, aiming to ensure the long-term accessibility and integrity of...

Continue Reading
Seritage Growth Properties Investors Alert: Class Action Lawsuit Update

Updated Category News Views 107

Notification of Class Action Lawsuit for Seritage Growth Properties Levi & Korsinsky, LLP is reaching out to inform investors of Seritage Growth Properties (NYSE: SRG) regarding an ongoing class action securities lawsuit. This case marks an important development for those affected by alleged securities fraud. Overview of the Class Action Lawsuit This lawsuit is centered...

Continue Reading